Composition and method for treating a hematological malignancy
AssigneeDana-Farber Cancer Institute, Inc.
InventorsRuben Carrasco, Jianjun Zhao
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for treating hematological malignancies, such as multiple myeloma, in a subject by increasing levels or activity of miR-30 RNA in plasma cells of the subject.
Claims31
A method for inhibiting BCL9 expression in a population of B cells in a first subject, the method comprising administering to the first subject a therapeutically effective amount of an agent comprising an miR-30 polynucleotide, wherein the population of B cells have a higher amount of BCL9 RNA or protein than a corresponding population of B cells from a second subject and wherein the second subject does not have multiple myeloma.
A method of reducing proliferation, survival, migration, or colony formation ability of multiple myeloma cells in a subject with multiple myeloma, the method comprising administering to the subject a therapeutically effective amount of an agent comprising an miR-30 polynucleotide, wherein the multiple myeloma cells have a higher amount of BCL9 RNA or protein than normal plasma cells.
A method of inhibiting metastasis of multiple myeloma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent comprising an miR-30 polynucleotide, wherein the multiple myeloma cells have a higher amount of BCL9 RNA or protein than normal plasma cells.
A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent comprising an miR-30 polynucleotide, wherein the hematological malignant cells have a higher amount of BCL9 RNA or protein than normal hematological cells.
Dependencies are inferred from the claim text.